Re: Cuba
Posted: Tue Oct 23, 2018 11:21 am
The scope of the Cuban vaccine against hepatitis B
Cuba has, since 2000, the achievement of null reports of cases of acute hepatitis B infection in children under five years, thanks to the political will to vaccinate a hundred percent of the child population free of charge
Author: Nuria Barbosa León | internet@granma.cu
October 22, 2018 20:10:50
In Cuba, the recombinant preventive vaccine against hepatitis b, Heberbiovac HB® has been produced for more than 25 years. Photo: Arnaldo Santos
Cuba has, since 2000, the achievement of null reports of cases of acute hepatitis B infection in children under five years, thanks to the political will to vaccinate 100% of the child population free of charge from the first hours after born the baby.
To this data should be added that, as of 2007, there are no reports of the disease until the age of 15, according to Dr. Zurina Cinza Estévez, in charge of the department of clinical studies of vaccines belonging to the sub-directorate of Clinical Investigations of the Center of Engineering. Genetics and Biotechnology (CIGB) of Havana.
To achieve these results, the recombinant preventive hepatitis B vaccine, Heberbiovac HB® , has been produced on the Caribbean island for more than 25 years . "Our vaccine does not depend on a cultivated virus, but on the recombinant protein that is obtained through the genetic information that is introduced into a yeast, to which its own genetic material is transformed. This yeast is capable of becoming a factory that, to the same extent that it produces enzymes and other substances for its functioning, generates the recombinant protein known by surface antigen of the hepatitis B virus, with which the vaccine is made, "explained the doctor.
«This surface antigen can be used in the production of the monovalent vaccine, that is, the specific vaccine and only against hepatitis B, or it can also be used in combination, forming part of the pentavalent vaccine, Heberpenta®-L, indicated for immunization against diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type B ».
More recently, HeberNasvac® , a therapeutic recombinant vaccine administered through the nose, combining some doses subcutaneously, was also obtained in Cuba . In this therapeutic vaccine a mixture of the surface antigen is used with another antigen also recombinant, the antigen of the nucleocapsid of the hepatitis B virus. The new formulation allows the interaction of antigens in the tonsils and stimulates both the systemic and the level of immunity of the mucous membranes.
HeberNasvac® is another option available to treat adult patients with chronic infection with hepatitis B virus. To date, it has shown an excellent safety profile with a reduced number of adverse reactions, of short duration and mild. The most frequent are: pain at the site of injection, sneezing, runny nose, nasal itching and light fever less than 38 degrees Celsius.
In addition, the treatment turns out to be shorter using a smaller amount of HeberNasvac® (15 doses in 20 weeks) compared to Pegylated Interferon (another medicine) that needs 48 doses in 48 weeks of treatment, or compared to the indefinite use of antiviral, usually prescribed for life, said the scientist, and assured the existence of the product to meet the needs of the Cuban population and with capacity to export to other nations.
Scientists have observed a post-treatment antiviral effect superior to other drugs in existence, with a specific immuno-modulating activity against the two recombinant proteins. There is also evidence of greater effectiveness in long-term follow-up and in difficult genotypes of the virus, with benefits for patients who have been treated before with other available medications, without having managed to control the infection.
IN CONTEXT
-Data provided by the World Health Organization (WHO) highlight the existence of 257 million people chronically infected with hepatitis B in the world, which could lead to liver cirrhosis or hepatocellular carcinoma in 25% of the patients, and be the cause of death for 650,000.
-The Pan American Health Organization (PAHO) reported in its reports that in the Americas region, 3.9 million people live with chronic hepatitis B and 7.2 million with chronic hepatitis C. Liver cancer is the fourth cause of death by this entity among men and the seventh among women in the Western Hemisphere.
- The Immunization Program of Cuba emerged in 1962 as a result of political and social transformations initiated in 1959, with the triumph of the Revolution, when communicable diseases, including those preventable by vaccines, caused the main morbidity and mortality in infants .
-The organization of the national health system has allowed some 4.8 million doses of simple or compound vaccines to be administered annually to protect against 13 diseases, including a pentavalent whose five components are produced in the country. The vaccination against hepatitis B in the first 24 hours after birth, was completed 19 years before the goal set by the WHO, thanks to the contribution of Cuban scientists.
-Hepatitis is an inflammation of the liver commonly caused by a viral infection by one of the five major viruses of hepatitis (types A, B, C, D and E). It can cause acute infections and progress to chronic liver disease, cirrhosis, cancer or even death.
- Hepatitis B and C infections are transmitted through infected blood, contaminated needles and syringes, and between people who inject drugs. In the case of hepatitis B it can also be transmitted through unprotected sex and from an infected mother to her newborn child. They usually manifest as chronic infections that can remain asymptomatic for long periods of time, often for years.
http://www.granma.cu/cuba/2018-10-22/el ... 8-20-10-50
Google Translator
Cuba has, since 2000, the achievement of null reports of cases of acute hepatitis B infection in children under five years, thanks to the political will to vaccinate a hundred percent of the child population free of charge
Author: Nuria Barbosa León | internet@granma.cu
October 22, 2018 20:10:50
In Cuba, the recombinant preventive vaccine against hepatitis b, Heberbiovac HB® has been produced for more than 25 years. Photo: Arnaldo Santos
Cuba has, since 2000, the achievement of null reports of cases of acute hepatitis B infection in children under five years, thanks to the political will to vaccinate 100% of the child population free of charge from the first hours after born the baby.
To this data should be added that, as of 2007, there are no reports of the disease until the age of 15, according to Dr. Zurina Cinza Estévez, in charge of the department of clinical studies of vaccines belonging to the sub-directorate of Clinical Investigations of the Center of Engineering. Genetics and Biotechnology (CIGB) of Havana.
To achieve these results, the recombinant preventive hepatitis B vaccine, Heberbiovac HB® , has been produced on the Caribbean island for more than 25 years . "Our vaccine does not depend on a cultivated virus, but on the recombinant protein that is obtained through the genetic information that is introduced into a yeast, to which its own genetic material is transformed. This yeast is capable of becoming a factory that, to the same extent that it produces enzymes and other substances for its functioning, generates the recombinant protein known by surface antigen of the hepatitis B virus, with which the vaccine is made, "explained the doctor.
«This surface antigen can be used in the production of the monovalent vaccine, that is, the specific vaccine and only against hepatitis B, or it can also be used in combination, forming part of the pentavalent vaccine, Heberpenta®-L, indicated for immunization against diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type B ».
More recently, HeberNasvac® , a therapeutic recombinant vaccine administered through the nose, combining some doses subcutaneously, was also obtained in Cuba . In this therapeutic vaccine a mixture of the surface antigen is used with another antigen also recombinant, the antigen of the nucleocapsid of the hepatitis B virus. The new formulation allows the interaction of antigens in the tonsils and stimulates both the systemic and the level of immunity of the mucous membranes.
HeberNasvac® is another option available to treat adult patients with chronic infection with hepatitis B virus. To date, it has shown an excellent safety profile with a reduced number of adverse reactions, of short duration and mild. The most frequent are: pain at the site of injection, sneezing, runny nose, nasal itching and light fever less than 38 degrees Celsius.
In addition, the treatment turns out to be shorter using a smaller amount of HeberNasvac® (15 doses in 20 weeks) compared to Pegylated Interferon (another medicine) that needs 48 doses in 48 weeks of treatment, or compared to the indefinite use of antiviral, usually prescribed for life, said the scientist, and assured the existence of the product to meet the needs of the Cuban population and with capacity to export to other nations.
Scientists have observed a post-treatment antiviral effect superior to other drugs in existence, with a specific immuno-modulating activity against the two recombinant proteins. There is also evidence of greater effectiveness in long-term follow-up and in difficult genotypes of the virus, with benefits for patients who have been treated before with other available medications, without having managed to control the infection.
IN CONTEXT
-Data provided by the World Health Organization (WHO) highlight the existence of 257 million people chronically infected with hepatitis B in the world, which could lead to liver cirrhosis or hepatocellular carcinoma in 25% of the patients, and be the cause of death for 650,000.
-The Pan American Health Organization (PAHO) reported in its reports that in the Americas region, 3.9 million people live with chronic hepatitis B and 7.2 million with chronic hepatitis C. Liver cancer is the fourth cause of death by this entity among men and the seventh among women in the Western Hemisphere.
- The Immunization Program of Cuba emerged in 1962 as a result of political and social transformations initiated in 1959, with the triumph of the Revolution, when communicable diseases, including those preventable by vaccines, caused the main morbidity and mortality in infants .
-The organization of the national health system has allowed some 4.8 million doses of simple or compound vaccines to be administered annually to protect against 13 diseases, including a pentavalent whose five components are produced in the country. The vaccination against hepatitis B in the first 24 hours after birth, was completed 19 years before the goal set by the WHO, thanks to the contribution of Cuban scientists.
-Hepatitis is an inflammation of the liver commonly caused by a viral infection by one of the five major viruses of hepatitis (types A, B, C, D and E). It can cause acute infections and progress to chronic liver disease, cirrhosis, cancer or even death.
- Hepatitis B and C infections are transmitted through infected blood, contaminated needles and syringes, and between people who inject drugs. In the case of hepatitis B it can also be transmitted through unprotected sex and from an infected mother to her newborn child. They usually manifest as chronic infections that can remain asymptomatic for long periods of time, often for years.
http://www.granma.cu/cuba/2018-10-22/el ... 8-20-10-50
Google Translator